In:
Journal of the American Heart Association, Ovid Technologies (Wolters Kluwer Health), Vol. 11, No. 12 ( 2022-06-21)
Abstract:
Catheter‐based slow‐pathway modification (SPM) is the treatment of choice for symptomatic atrioventricular nodal reentrant tachycardia (AVNRT). We sought to investigate the interactions between patient age and procedural outcomes in pediatric patients undergoing catheter‐based SPM for AVNRT. Methods and Results A retrospective cohort study was performed, including consecutive patients undergoing acutely successful SPM for AVNRT from 2008 to 2017. Those with congenital heart disease, cardiomyopathy, and accessory pathways were excluded. Patients were stratified by age quartile at time of SPM. The primary outcome was AVNRT recurrence. A total of 512 patients underwent successful SPM for AVNRT. Age quartile 1 had 129 patients with a median age and weight of 8.9 years and 30.6 kg, respectively. Radiofrequency energy was used in 98% of cases. Follow‐up was available in 447 (87%) patients with a median duration of 0.8 years (interquartile range, 0.2–2.5 years). AVNRT recurred in 22 patients. Multivariable Cox proportional hazard modeling identified atypical AVNRT (hazard ratio [HR] , 5.83; 95% CI, 2.01–16.96; P =0.001), dual atrioventricular nodal only (HR, 4.09; 95% CI, 1.39–12.02; P =0.011), total radiofrequency lesions (HR, 1.06 per lesion; 95% CI, 1.01–1.12; P =0.032), and the use of a long sheath (HR, 3.52; 95% CI, 1.23–10.03; P =0.010) as predictors of AVNRT recurrence; quartile 1 patients were not at higher risk of recurrence (HR, 0.45; 95% CI, 0.10–1.97; P =0.29). Complete heart block requiring permanent pacing occurred in one quartile 2 patient at 14.9 years of age. Conclusions Pediatric AVNRT can be treated with radiofrequency‐SPM with high procedural efficacy and minimal risk of complications, including heart block. Atypical AVNRT and dual atrioventricular nodal physiology without inducible tachycardia remain challenging substrates.
Type of Medium:
Online Resource
ISSN:
2047-9980
DOI:
10.1161/JAHA.121.022799
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2022
detail.hit.zdb_id:
2653953-6
